This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2025 Jul 24;393(4):411-412.

doi: 10.1056/NEJMc2507989.

Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). Reply

Steven E Nissen¹, Ann Marie Navar², John H Krege³

Affiliations

Affiliations

¹ Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
² University of Texas, Southwestern Medical Center, Dallas.
³ Eli Lilly, Indianapolis.

PMID: 40700701
DOI: 10.1056/NEJMc2507989

Comment

Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). Reply

Steven E Nissen et al. N Engl J Med. 2025.

. 2025 Jul 24;393(4):411-412.

doi: 10.1056/NEJMc2507989.

Authors

Steven E Nissen¹, Ann Marie Navar², John H Krege³

Affiliations

¹ Cleveland Clinic Coordinating Center for Clinical Research, Cleveland.
² University of Texas, Southwestern Medical Center, Dallas.
³ Eli Lilly, Indianapolis.

PMID: 40700701
DOI: 10.1056/NEJMc2507989

No abstract available

PubMed Disclaimer

Comment on

Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).
Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, Wolski K, Michael L, Haupt A, Krege JH; ALPACA Trial Investigators. Nissen SE, et al. N Engl J Med. 2025 May 1;392(17):1673-1683. doi: 10.1056/NEJMoa2415818. Epub 2025 Mar 30. N Engl J Med. 2025. PMID: 40162643 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.